Trial · NCT03559192
Participant flow27
How many started, completed or left each group, period by period.
1 to 20 of 27
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Lead-in Period (3 Weeks) | STARTED | Lead in Period: Placebo | 181 | |
| Lead-in Period (3 Weeks) | STARTED | Double-blind Treatment + Withdrawal Period: Placebo | 0 | |
| Lead-in Period (3 Weeks) | STARTED | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 0 | |
| Lead-in Period (3 Weeks) | COMPLETED | Lead in Period: Placebo | 169 | |
| Lead-in Period (3 Weeks) | COMPLETED | Double-blind Treatment + Withdrawal Period: Placebo | 0 | |
| Lead-in Period (3 Weeks) | COMPLETED | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 0 | |
| Lead-in Period (3 Weeks) | NOT COMPLETED | Lead in Period: Placebo | 12 | |
| Lead-in Period (3 Weeks) | NOT COMPLETED | Double-blind Treatment + Withdrawal Period: Placebo | 0 | |
| Lead-in Period (3 Weeks) | NOT COMPLETED | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 0 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | STARTED | Lead in Period: Placebo | 0 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | STARTED | Double-blind Treatment + Withdrawal Period: Placebo | 84 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | STARTED | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 85 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | Placebo Lead-in Responders | Lead in Period: Placebo | 0 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | Placebo Lead-in Responders | Double-blind Treatment + Withdrawal Period: Placebo | 22 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | Placebo Lead-in Responders | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 23 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | Placebo Lead-In Non-Responders | Lead in Period: Placebo | 0 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | Placebo Lead-In Non-Responders | Double-blind Treatment + Withdrawal Period: Placebo | 62 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | Placebo Lead-In Non-Responders | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 62 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | Completed DB Period and Entered Withdrawal | Lead in Period: Placebo | 0 | |
| DB Treatment(6 Wks) + Withdrawal(2 Wks) | Completed DB Period and Entered Withdrawal | Double-blind Treatment + Withdrawal Period: Placebo | 81 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03559192/flow